Antonio Sisinni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonio Sisinni has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Luca Testa
IRCCS Policlinico San Donato
6 shared publications - Enrico Poletti
Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA; Hartcentrum Ziekenhuis aan de Stroom (ZAS) Middelheim, Antwerp, Belgium; Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium
5 shared publications Damiano Regazzoli
IRCCS Humanitas Research Hospital Department of Cardiology Rozzano, Milan
4 shared publicationsFrancesco Bedogni
IRCCS Policlinico San Donato
4 shared publicationsMaurizio Taramasso
Herzzentrum Hirslanden Zurich, Klinik Hirslanden, Switzerland (M.T.).
4 shared publicationsAlberto Margonato
Cardiology Unit, Heart Valve Center, IRCCS Ospedale San Raffaele, Milan, Italy (C.G., A. Margonato)
3 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (3)
Latest-iteration self-expanding vs balloon-expandable transcatheter heart valves for failed surgical bioprostheses
Background: Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is increasingly performed in degenerated surgical bioprostheses, although data concerning the performance of latest iterations of transcatheter heart valves (THVs) are scarce. Aims: We aimed to compare procedural, clinical and haemodynamic outcomes of latest-generation THVs in ViV TAVI. Methods and Results: This multicenter retrospective study included 381 consecutive patients undergoing ViV TAVI, 294 with self-expanding (SE), and 87 with a balloon expandable (BE) THV. Primary efficacy endpoints were Valve Academic Research Consortium (VARC)-3 technical and device success. Primary safety outcomes were all-cause death and re-hospitalization for heart failure (HF). Patients receiving SE valves were older (79 vs 75 years, P < .001). Time from surgery to ViV was longer in BE group (4 vs 3 years, P = .041). A numerically higher rate of coronary obstruction (4% vs 0%, P = .076) was observed in SE THVs, despite a more frequent coronary protection (24% vs 14%, P = .045). Technical (95% vs 98%, P = .380) and device success (89% vs 79%, P = .105) were similar. At 1 year, SE valves showed significantly lower mean gradients (14 ± 8 vs 21 ± 8 mmHg, P < .001). Rates of paravalvular leak and patient–prosthesis mismatch did not differ between groups. All-cause mortality (5% vs 4%, P = .928) and re-hospitalization for HF (4% vs 2%, P = .507) was also comparable among SE and BE, likewise myocardial infarction, stroke, and permanent pacemaker implantation. Conclusion: Latest iterations of SE and BE THVs provided favourable outcomes in ViV TAVI, without significant differences in safety/efficacy profile. SE platforms achieved lower residual gradients at 1 year.
- 1 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (3)
Open AccessLatest-iteration self-expanding vs balloon-expandable transcatheter heart valves for failed surgical bioprostheses
Background: Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is increasingly performed in degenerated surgical bioprostheses, although data concerning the performance of latest iterations of transcatheter heart valves (THVs) are scarce. Aims: We aimed to compare procedural, clinical and haemodynamic outcomes of latest-generation THVs in ViV TAVI. Methods and Results: This multicenter retrospective study included 381 consecutive patients undergoing ViV TAVI, 294 with self-expanding (SE), and 87 with a balloon expandable (BE) THV. Primary efficacy endpoints were Valve Academic Research Consortium (VARC)-3 technical and device success. Primary safety outcomes were all-cause death and re-hospitalization for heart failure (HF). Patients receiving SE valves were older (79 vs 75 years, P < .001). Time from surgery to ViV was longer in BE group (4 vs 3 years, P = .041). A numerically higher rate of coronary obstruction (4% vs 0%, P = .076) was observed in SE THVs, despite a more frequent coronary protection (24% vs 14%, P = .045). Technical (95% vs 98%, P = .380) and device success (89% vs 79%, P = .105) were similar. At 1 year, SE valves showed significantly lower mean gradients (14 ± 8 vs 21 ± 8 mmHg, P < .001). Rates of paravalvular leak and patient–prosthesis mismatch did not differ between groups. All-cause mortality (5% vs 4%, P = .928) and re-hospitalization for HF (4% vs 2%, P = .507) was also comparable among SE and BE, likewise myocardial infarction, stroke, and permanent pacemaker implantation. Conclusion: Latest iterations of SE and BE THVs provided favourable outcomes in ViV TAVI, without significant differences in safety/efficacy profile. SE platforms achieved lower residual gradients at 1 year.
- 12 May 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (2) , 314-322
Prognostic Impact of Pacemaker Implantation in Transcatheter Aortic Valve Replacement With Self‐Expanding Prosthesis
Background: With the progressively increasing number of low‐risk patients undergoing transcatheter aortic valve replacement (TAVR), the number of those who will be long‐time pacemaker (PM) carriers is expected to increase. To date, conflicting data is available regarding the association between PM and mortality following TAVR. Aims: To investigate the association between PM and mortality in patients undergoing TAVR with self‐expandable bio‐prosthesis. Methods: Patients undergoing TAVR between 2007 and 2014 in 10 Italian centers were considered. Two analyses were performed: one comparing patients with and without pre‐TAVR PM (primary) and one comparing those with and without post‐TAVR PM (secondary). The primary endpoint was all‐cause mortality; the secondary endpoint was re‐hospitalization to the cardiac ward. Clinical outcomes were assessed at the longest available follow‐up. Results: Overall, 1779 patients were included in the primary analysis and 1465 in the secondary one. Pre‐TAVR PM implantation was not associated with an increased risk of all cause death in both the primary (adj. HR 0.93, 95% CI 0.76−1.13; p = 0.475) and secondary analysis (adj. HR 0.83, 95% CI 0.71−0.98; p = 0.029). Regarding hospitalization to cardiac ward, pre‐TAVR PM was not associated with the outcome (adj. HR 1.10, 95% CI 0.85−1.42, p = 0.254), while post‐TAVR PM implantation was related with an increased risk (adj. HR 1.94, 95% CI 1.56−2.41; p < 0.001). Conclusions: PM implantation is not associated with an increased risk of mortality in patients undergoing TAVR.
- 12 May 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (2) , 314-322
Prognostic Impact of Pacemaker Implantation in Transcatheter Aortic Valve Replacement With Self‐Expanding Prosthesis
Background: With the progressively increasing number of low‐risk patients undergoing transcatheter aortic valve replacement (TAVR), the number of those who will be long‐time pacemaker (PM) carriers is expected to increase. To date, conflicting data is available regarding the association between PM and mortality following TAVR. Aims: To investigate the association between PM and mortality in patients undergoing TAVR with self‐expandable bio‐prosthesis. Methods: Patients undergoing TAVR between 2007 and 2014 in 10 Italian centers were considered. Two analyses were performed: one comparing patients with and without pre‐TAVR PM (primary) and one comparing those with and without post‐TAVR PM (secondary). The primary endpoint was all‐cause mortality; the secondary endpoint was re‐hospitalization to the cardiac ward. Clinical outcomes were assessed at the longest available follow‐up. Results: Overall, 1779 patients were included in the primary analysis and 1465 in the secondary one. Pre‐TAVR PM implantation was not associated with an increased risk of all cause death in both the primary (adj. HR 0.93, 95% CI 0.76−1.13; p = 0.475) and secondary analysis (adj. HR 0.83, 95% CI 0.71−0.98; p = 0.029). Regarding hospitalization to cardiac ward, pre‐TAVR PM was not associated with the outcome (adj. HR 1.10, 95% CI 0.85−1.42, p = 0.254), while post‐TAVR PM implantation was related with an increased risk (adj. HR 1.94, 95% CI 1.56−2.41; p < 0.001). Conclusions: PM implantation is not associated with an increased risk of mortality in patients undergoing TAVR.
- Open Access
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e046180
Supra‐Annular Versus Intra‐Annular Devices for Transcatheter Aortic Valve‐in‐Valve Replacement: The PANDORA International Registry
Background: As transcatheter aortic valve replacement (TAVR) expands to younger, lower‐risk populations, the need for repeat procedures due to valve degeneration is expected to increase. TAVR‐in‐TAVR has emerged as a feasible strategy, although outcomes across supra‐annular (SAV) and intra‐annular (IAV) valve combinations remain unclear. The PANDORA (Supra‐Annular Versus Intra‐Annular Devices for TAVR‐in‐TAVR) international registry study assessed safety, hemodynamic performance, and clinical outcomes of TAVR‐in‐TAVR according to prosthetic configurations. Methods: From an international multicenter registry (2011–2024), 172 TAVR‐in‐TAVR cases were identified among ≈30 000 TAVR procedures, with a median interval of 1401 days. Patients were stratified into 4 groups: SAV‐IAV (n=32), SAV‐SAV (n=29), IAV‐SAV (n=74), and IAV‐IAV (n=37). Results: CoreValve/Evolut (49.4%) and Edwards SAPIEN (35.5%) were the most frequent index prostheses, whereas the second valve was mainly Edwards SAPIEN (60.5%), followed by Evolut (35.5%) and Myval/Octacor (4.0%). Structural valve deterioration was the leading failure mechanism (77.9%), while nonstructural valve deterioration dysfunction, alone or combined with structural valve deterioration, occurred in 40.7%. Overall Valve Academic Research Consortium 3 technical success was 91.3%, numerically highest in SAV‐IAV and IAV‐SAV ( P =0.090). Thirty‐day device success was 68%, also higher in SAV‐IAV (75.9%, P =0.301), mainly influenced by elevated residual gradients (≥20 mm Hg in 12.7%) and the 30‐day mortality rate (7.3%). At 1 year, the IAV‐IAV group showed the numerically lowest freedom from death and heart failure hospitalization (76.1%, P =0.734). Male sex and chronic kidney disease independently predicted death at follow‐up. Conclusions: TAVR‐in‐TAVR is feasible with generally favorable outcomes, although clinical and procedural profiles vary by the different prosthesis combinations. These findings highlight the need for further studies to refine device selection strategies.
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e046180
Open AccessSupra‐Annular Versus Intra‐Annular Devices for Transcatheter Aortic Valve‐in‐Valve Replacement: The PANDORA International Registry
Background: As transcatheter aortic valve replacement (TAVR) expands to younger, lower‐risk populations, the need for repeat procedures due to valve degeneration is expected to increase. TAVR‐in‐TAVR has emerged as a feasible strategy, although outcomes across supra‐annular (SAV) and intra‐annular (IAV) valve combinations remain unclear. The PANDORA (Supra‐Annular Versus Intra‐Annular Devices for TAVR‐in‐TAVR) international registry study assessed safety, hemodynamic performance, and clinical outcomes of TAVR‐in‐TAVR according to prosthetic configurations. Methods: From an international multicenter registry (2011–2024), 172 TAVR‐in‐TAVR cases were identified among ≈30 000 TAVR procedures, with a median interval of 1401 days. Patients were stratified into 4 groups: SAV‐IAV (n=32), SAV‐SAV (n=29), IAV‐SAV (n=74), and IAV‐IAV (n=37). Results: CoreValve/Evolut (49.4%) and Edwards SAPIEN (35.5%) were the most frequent index prostheses, whereas the second valve was mainly Edwards SAPIEN (60.5%), followed by Evolut (35.5%) and Myval/Octacor (4.0%). Structural valve deterioration was the leading failure mechanism (77.9%), while nonstructural valve deterioration dysfunction, alone or combined with structural valve deterioration, occurred in 40.7%. Overall Valve Academic Research Consortium 3 technical success was 91.3%, numerically highest in SAV‐IAV and IAV‐SAV ( P =0.090). Thirty‐day device success was 68%, also higher in SAV‐IAV (75.9%, P =0.301), mainly influenced by elevated residual gradients (≥20 mm Hg in 12.7%) and the 30‐day mortality rate (7.3%). At 1 year, the IAV‐IAV group showed the numerically lowest freedom from death and heart failure hospitalization (76.1%, P =0.734). Male sex and chronic kidney disease independently predicted death at follow‐up. Conclusions: TAVR‐in‐TAVR is feasible with generally favorable outcomes, although clinical and procedural profiles vary by the different prosthesis combinations. These findings highlight the need for further studies to refine device selection strategies.
- Open Access
- 5 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8627
Modern Imaging Techniques for Percutaneous Coronary Intervention Guidance: A Focus on Intravascular Ultrasound and Optical Coherence Tomography
The use of imaging during percutaneous coronary intervention (PCI) can improve the outcomes by giving key information in every phase of the procedure. It can improve the knowledge of plaque composition thus helping the subsequent technical strategy; it can precisely define the measure of the stent to implant; it can assess in detail the correct positioning of the stent (apposition, expansion, and full coverage of the atherosclerotic plaque); it helps in recognizing the complications that may occur after stenting (e.g., edge dissection or tissue/thrombus protrusion in the stent area). Further, it could help evaluation for both diagnostic and therapeutic purposes of angiographic unknown or questionable findings [e.g., spontaneous coronary artery dissection (SCAD), characterization of mycotic aneurysm and pseudoaneurysm]. In the follow up phase, the use of intracoronary imaging may significantly improve the understanding of the mechanisms leading to the procedural failure. What this review adds is to describe the similarities and differences between intravascular ultrasound (IVUS) and optical coherence tomography (OCT) technologies, to highlight the evidence supporting their utility to improve PCI outcomes, to give practical advice and tools on daily interventional routine, to show a point of view on future perspectives and integration with artificial intelligence (AI).
- 5 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8627
Open AccessModern Imaging Techniques for Percutaneous Coronary Intervention Guidance: A Focus on Intravascular Ultrasound and Optical Coherence Tomography
The use of imaging during percutaneous coronary intervention (PCI) can improve the outcomes by giving key information in every phase of the procedure. It can improve the knowledge of plaque composition thus helping the subsequent technical strategy; it can precisely define the measure of the stent to implant; it can assess in detail the correct positioning of the stent (apposition, expansion, and full coverage of the atherosclerotic plaque); it helps in recognizing the complications that may occur after stenting (e.g., edge dissection or tissue/thrombus protrusion in the stent area). Further, it could help evaluation for both diagnostic and therapeutic purposes of angiographic unknown or questionable findings [e.g., spontaneous coronary artery dissection (SCAD), characterization of mycotic aneurysm and pseudoaneurysm]. In the follow up phase, the use of intracoronary imaging may significantly improve the understanding of the mechanisms leading to the procedural failure. What this review adds is to describe the similarities and differences between intravascular ultrasound (IVUS) and optical coherence tomography (OCT) technologies, to highlight the evidence supporting their utility to improve PCI outcomes, to give practical advice and tools on daily interventional routine, to show a point of view on future perspectives and integration with artificial intelligence (AI).
- 1 November 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (11) , e012489
Hemodynamic Right Heart Catheterization Before Transcatheter Mitral and Tricuspid Therapies
Recent findings emphasize the potential role of invasive hemodynamic assessment in guiding transcatheter mitral and tricuspid valve percutaneous interventions. Right heart catheterization-derived parameters offer insights into hemodynamic changes associated with valvular heart diseases, pulmonary hypertension phenotyping, and right ventricular to pulmonary artery coupling. This might improve prognostic stratification for candidates to transcatheter therapies. This review provides a clinical overview of available data regarding the utility of preoperative right heart catheterization-derived parameters in patients undergoing mitral and tricuspid percutaneous repair or replacement.
- 1 November 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (11) , e012489
Hemodynamic Right Heart Catheterization Before Transcatheter Mitral and Tricuspid Therapies
Recent findings emphasize the potential role of invasive hemodynamic assessment in guiding transcatheter mitral and tricuspid valve percutaneous interventions. Right heart catheterization-derived parameters offer insights into hemodynamic changes associated with valvular heart diseases, pulmonary hypertension phenotyping, and right ventricular to pulmonary artery coupling. This might improve prognostic stratification for candidates to transcatheter therapies. This review provides a clinical overview of available data regarding the utility of preoperative right heart catheterization-derived parameters in patients undergoing mitral and tricuspid percutaneous repair or replacement.
- 10 October 2025
- Published by Elsevier in The American Journal of Cardiology
- Vol. 257, 191-192
3D Mitral Valve Area Impact on Postprocedural Gradient after M-TEER with Single Clip Deployment
- 10 October 2025
- Published by Elsevier in The American Journal of Cardiology
- Vol. 257, 191-192
3D Mitral Valve Area Impact on Postprocedural Gradient after M-TEER with Single Clip Deployment
- Open Access
- 13 September 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (10) , 102153
Impact of Precapillary Component of Pulmonary Pressure in Tricuspid Transcatheter Edge-to-Edge Repair
- 13 September 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (10) , 102153
Open AccessImpact of Precapillary Component of Pulmonary Pressure in Tricuspid Transcatheter Edge-to-Edge Repair
- Open Access
- 28 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (9) , 3051
Facing Complexity: Outcomes of Surgical Bailouts from Complications of Transcatheter Aortic Valve Replacement in a Single High-Volume Center
Background: Transcatheter aortic valve replacement (TAVR) is at the forefront of structural heart programs all over the world. With a growing number of TAVR procedures in lower-risk and younger patients, acute and chronic complications require decisive treatment. The aim of the present study is to retrospectively analyze the efficacy of surgical bailout strategies in case of complications from TAVR that had been performed in the highest-volume center in Italy over the past ten years. Methods: Acute complications were defined as events occurring in the first 24 h after surgery, while chronic complications were defined as events occurring within the first year post-implant. We retrospectively analyzed the 2731 patients who had undergone TAVR at our institution from January 2015 to August 2024. Results: A total of 21 patients were included, with a median age of 78 years (IQR 11y). The majority of patients underwent TAVR with a self-expanding prosthesis (76%). A total of 11 patients (52%) presented acute complications, of which the most common were aortic dissection (n = 4 [19%]) followed by left ventricular perforation (n = 3 [14%]). The most common chronic complication was early endocarditis (n = 5 [24%]). The most common bailout strategy was aortic valve replacement (AVR), which was sufficient in 10 patients (48%), followed by complete root replacement (n = 4 [19%]). In-hospital mortality was higher in acute compared with chronic complications albeit not statistically significant (n = 4 [36%] vs. n = 2 [20%], p = 0.64), highlighting the very high risk of all these surgeries. Conclusions: Bailout and post-TAVR surgery are critical issues, with overall acceptable yet significant mortality considering the very high risk of these procedures. In our experience, half of the overall complications cannot be resolved with a simple explant and subsequent valve replacement, thereby underlining the importance of skilled cardiothoracic surgery teams on site to address complex issues such as ventricular perforation and emergency aortic/root replacement.
- 28 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (9) , 3051
Open AccessFacing Complexity: Outcomes of Surgical Bailouts from Complications of Transcatheter Aortic Valve Replacement in a Single High-Volume Center
Background: Transcatheter aortic valve replacement (TAVR) is at the forefront of structural heart programs all over the world. With a growing number of TAVR procedures in lower-risk and younger patients, acute and chronic complications require decisive treatment. The aim of the present study is to retrospectively analyze the efficacy of surgical bailout strategies in case of complications from TAVR that had been performed in the highest-volume center in Italy over the past ten years. Methods: Acute complications were defined as events occurring in the first 24 h after surgery, while chronic complications were defined as events occurring within the first year post-implant. We retrospectively analyzed the 2731 patients who had undergone TAVR at our institution from January 2015 to August 2024. Results: A total of 21 patients were included, with a median age of 78 years (IQR 11y). The majority of patients underwent TAVR with a self-expanding prosthesis (76%). A total of 11 patients (52%) presented acute complications, of which the most common were aortic dissection (n = 4 [19%]) followed by left ventricular perforation (n = 3 [14%]). The most common chronic complication was early endocarditis (n = 5 [24%]). The most common bailout strategy was aortic valve replacement (AVR), which was sufficient in 10 patients (48%), followed by complete root replacement (n = 4 [19%]). In-hospital mortality was higher in acute compared with chronic complications albeit not statistically significant (n = 4 [36%] vs. n = 2 [20%], p = 0.64), highlighting the very high risk of all these surgeries. Conclusions: Bailout and post-TAVR surgery are critical issues, with overall acceptable yet significant mortality considering the very high risk of these procedures. In our experience, half of the overall complications cannot be resolved with a simple explant and subsequent valve replacement, thereby underlining the importance of skilled cardiothoracic surgery teams on site to address complex issues such as ventricular perforation and emergency aortic/root replacement.
- Open Access
- 21 January 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (2) , e037070
Real‐World Experience in Tricuspid Transcatheter Edge‐to‐Edge Repair: Transcatheter Tricuspid Valve Repair in Spain Registry
Background: Significant tricuspid regurgitation (TR) is associated with increased morbidity and mortality. The development of transcatheter valve repair therapies has opened a wide range of opportunities for treatment of patients with high surgical risk. Real‐world data might improve patient selection and outcome. The authors sought to investigate acute and short‐term cardiovascular outcomes of tricuspid transcatheter edge‐to‐edge repair (T‐TEER) with dedicated devices in a real‐world setting. Methods and Results: This is a retrospective, single‐arm, multicenter registry conducted at 15 sites in Spain. The primary end point was a composite of all‐cause death, rehospitalization for heart failure, and tricuspid valve re‐intervention. Patients included (n=283) were older (76±9 years, 70% female), and showed significant comorbidities. Massive or torrential TR was present in 55% of subjects, with secondary cause being the main mechanism of regurgitation in ≈80% of individuals. Intraprocedural success was achieved in 79% of patients. At 1‐year follow‐up, significant improvements in TR grade (≥3+, 100% to 25%, P P P =0.012), was found to be an independent predictor of primary end point. Conclusions: In a real‐world contemporary setting, tricuspid transcatheter edge‐to‐edge repair with dedicated devices emerged as effective therapeutic option for patients with severe TR.
- 21 January 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (2) , e037070
Open AccessReal‐World Experience in Tricuspid Transcatheter Edge‐to‐Edge Repair: Transcatheter Tricuspid Valve Repair in Spain Registry
Background: Significant tricuspid regurgitation (TR) is associated with increased morbidity and mortality. The development of transcatheter valve repair therapies has opened a wide range of opportunities for treatment of patients with high surgical risk. Real‐world data might improve patient selection and outcome. The authors sought to investigate acute and short‐term cardiovascular outcomes of tricuspid transcatheter edge‐to‐edge repair (T‐TEER) with dedicated devices in a real‐world setting. Methods and Results: This is a retrospective, single‐arm, multicenter registry conducted at 15 sites in Spain. The primary end point was a composite of all‐cause death, rehospitalization for heart failure, and tricuspid valve re‐intervention. Patients included (n=283) were older (76±9 years, 70% female), and showed significant comorbidities. Massive or torrential TR was present in 55% of subjects, with secondary cause being the main mechanism of regurgitation in ≈80% of individuals. Intraprocedural success was achieved in 79% of patients. At 1‐year follow‐up, significant improvements in TR grade (≥3+, 100% to 25%, P P P =0.012), was found to be an independent predictor of primary end point. Conclusions: In a real‐world contemporary setting, tricuspid transcatheter edge‐to‐edge repair with dedicated devices emerged as effective therapeutic option for patients with severe TR.
- 8 July 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (13) , 1597-1606
Performance of Purpose-Built vs Off-Label Transcatheter Devices for Aortic Regurgitation
- 8 July 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (13) , 1597-1606
Performance of Purpose-Built vs Off-Label Transcatheter Devices for Aortic Regurgitation